Anthony Portale, MD

Education
Residency, - School of Medicine, University of California, San Francisco
Websites
Publications
  1. Impact of Burosumab Compared with Conventional Therapy in Younger Versus Older Children with X-Linked Hypophosphatemia.
  2. A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.
  3. Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia.
  4. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.
  5. Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia.
  6. Association Between Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) and Cognition in Children: Chronic Kidney Disease in Children (CKiD) Study.
  7. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial.
  8. Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD.
  9. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.
  10. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
  11. Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to <?6 years with chronic kidney disease receiving dialysis.
  12. An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to <?6 years with chronic kidney disease receiving dialysis.
  13. Vitamin D insufficiency, hemoglobin, and anemia in children with chronic kidney disease.
  14. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
  15. Waist-to-height ratio, body mass index, and cardiovascular risk profile in children with chronic kidney disease.
  16. Burosumab Therapy in Children with X-Linked Hypophosphatemia.
  17. Time-varying coefficient of determination to quantify the explanatory power of biomarkers on longitudinal GFR among children with chronic kidney disease.
  18. Rickets.
  19. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
  20. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
  21. Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia.
  22. Effect of Immigration Status on Outcomes in Pediatric Kidney Transplant Recipients.
  23. Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule.
  24. Prevalence and correlates of 25-hydroxyvitamin D deficiency in the Chronic Kidney Disease in Children (CKiD) cohort.
  25. Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia.
  26. Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study.
  27. Association of Body Mass Index with Patient-Centered Outcomes in Children with ESRD.
  28. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23.
  29. State level variations in nephrology workforce and timing and incidence of dialysis in the United States among children and adults: a retrospective cohort study.
  30. Malcolm A. Holliday, M.D, January 12, 1924 - March 26, 2014.
  31. Use of pedometers to increase physical activity among children and adolescents with chronic kidney disease.
  32. Disordered FGF23 and mineral metabolism in children with CKD.
  33. FGF-23 regulates CYP27B1 transcription in the kidney and in extra-renal tissues.
  34. Combined pancreatic islet and kidney transplantation in a child with unstable type 1 diabetes and end-stage renal disease.
  35. Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone.
  36. The clinical impact of humoral immunity in pediatric renal transplantation.
  37. A peripheral blood diagnostic test for acute rejection in renal transplantation.
  38. Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-up.
  39. Pedometer-assessed physical activity in children and young adults with CKD.
  40. Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice.
  41. Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23.
  42. Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice.
  43. Emerging topics in pediatric bone and mineral disorders 2008.
  44. Being overweight modifies the association between cardiovascular risk factors and microalbuminuria in adolescents.
  45. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro.
  46. Vitamin D 1alpha-hydroxylase gene mutations in patients with 1alpha-hydroxylase deficiency.
  47. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men.
  48. Persistent secondary hyperparathyroidism after renal transplantation in children.
  49. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice.
  50. Nephrogenic syndrome of inappropriate antidiuresis.
  51. Disordered regulation of renal 25-hydroxyvitamin D-1alpha-hydroxylase gene expression by phosphorus in X-linked hypophosphatemic (hyp) mice.
  52. Vitamin D biosynthesis and vitamin D 1 alpha-hydroxylase deficiency.
  53. Novel gene mutations in patients with 1alpha-hydroxylase deficiency that confer partial enzyme activity in vitro.
  54. The mechanism of 1,25-dihydroxyvitamin D(3) autoregulation in keratinocytes.
  55. Dietary phosphorus transcriptionally regulates 25-hydroxyvitamin D-1alpha-hydroxylase gene expression in the proximal renal tubule.
  56. Genetics of vitamin D biosynthesis and its disorders.
  57. Renal expression of the sodium/phosphate cotransporter gene, Npt2, is not required for regulation of renal 1 alpha-hydroxylase by phosphate.
  58. Vitamin D 1 alpha-hydroxylase.
  59. Human 25-hydroxyvitamin D-1alpha-hydroxylase: cloning, mutations, and gene expression.
  60. Altered diurnal regulation of blood ionized calcium and serum parathyroid hormone concentrations during parenteral nutrition.
  61. Genetic disorders of vitamin D biosynthesis.
  62. Genetic causes of rickets.
  63. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure.
  64. Genetics of vitamin D 1alpha-hydroxylase deficiency in 17 families.
  65. Hereditary rickets revealed.
  66. Reduced expression of the renal calcium-sensing receptor in rats with experimental chronic renal insufficiency.
  67. Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1.
  68. Complete structure of the human gene for the vitamin D 1alpha-hydroxylase, P450c1alpha.
  69. Aging alters calcium regulation of serum concentration of parathyroid hormone in healthy men.
  70. Aging and renal responsiveness to parathyroid hormone in healthy men.
  71. Effect of aging on the metabolism of phosphorus and 1,25-dihydroxyvitamin D in healthy men.
  72. Resolution of hepatitis B virus-related membranoproliferative glomerulonephritis after orthotopic liver transplantation.
  73. Renal transplantation without chronic immunosuppression after T cell-depleted, HLA-mismatched bone marrow transplantation.
  74. Acute post-streptococcal glomerulonephritis in a renal allograft.
  75. Metabolic acidosis reverses the increase in serum 1,25(OH)2D in phosphorus-restricted normal men.
  76. Progestin antagonism of estrogen stimulated 1,25-dihydroxyvitamin D levels.
  77. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism.
  78. Are blood transfusions beneficial in the cyclosporine era?
  79. Pathogenesis of secondary hyperparathyroidism in chronic renal insufficiency.
  80. Dietary potassium influences kidney maintenance of serum phosphorus concentration.
  81. Production and metabolic clearance of 1,25-dihydroxyvitamin D in men: effect of advancing age.
  82. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men.
  83. Pregnancy complicated by maternal spina bifida. A report of two cases.
  84. Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D.
  85. Evidence for a difference in vitamin D metabolism between spontaneously hypertensive and Wistar-Kyoto rats.
  86. Comparison of continuous ambulatory peritoneal dialysis and hemodialysis in children.
  87. Liquid-chromatographic measurements of inosine, hypoxanthine, and xanthine in studies of fructose-induced degradation of adenine nucleotides in humans and rats.
  88. Renal osteodystrophy in children: the role of vitamin D, phosphorus, and parathyroid hormone.
  89. Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans.
  90. Serum concentration of 1,25-dihydroxyvitamin D in the human: diurnal variation.
  91. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.
  92. Hemoperfusion in a child who ingested diquat and died from pontine infarction and hemorrhage.
  93. Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency.
  94. [Clinical study of the effects of metisoprinol in the treatment of mumps in adults].
  95. Nutritional management of chronic renal disease.